ABSTRACT
Background: Liver disorders present significant challenges to public health, necessitating the exploration of novel therapeutic strategies. Isofraxidin, a natural compound found in various plants, has shown promising pharmacological properties, including anti-inflammatory and antioxidant effects. However, its potential as a therapeutic agent for liver disorders through the modulation of human liver enzymes remains to be fully elucidated.
Aim: This study aimed to investigate the in vitro inhibitory effects of isofraxidin on human liver enzymes, with a focus on assessing its potential therapeutic relevance for liver disorders.
Methods: Human liver enzymes were isolated and incubated with varying concentrations of isofraxidin. Enzyme activity assays were conducted to assess the inhibitory effects of isofraxidin on key liver enzymes involved in metabolic and detoxification processes, including cytochrome P450 enzymes and phase II enzymes. Concentration-response curves were generated to determine the potency of isofraxidin as an enzyme inhibitor.
Results: Our findings revealed that isofraxidin exhibited dose-dependent inhibitory effects on human liver enzymes, including cytochrome P450 enzymes and phase II enzymes. The inhibitory potency varied among different enzymes, with certain enzymes showing higher sensitivity to isofraxidin inhibition compared to others. Additionally, we observed a favorable selectivity profile of isofraxidin, indicating its potential as a specific modulator of liver enzyme activity.
Conclusion: The results of this study demonstrate the inhibitory effects of isofraxidin on human liver enzymes in vitro, suggesting its potential as a therapeutic agent for liver disorders. The selective modulation of liver enzyme activity by isofraxidin highlights its promise as a targeted approach for the management of hepatic conditions. Further in vivo studies are warranted to validate the therapeutic efficacy and safety of isofraxidin in the treatment of liver disorders.
Keywords: Isofraxidin, liver enzymes, inhibition, in vitro, therapeutic strategy, liver disorders.